본문으로 건너뛰기
← 뒤로

Interrogating the immune landscape of microsatellite stable RAS-mutated colon cancer.

1/5 보강
Molecular oncology 📖 저널 OA 86.2% 2023: 1/1 OA 2024: 6/6 OA 2025: 42/47 OA 2026: 51/62 OA 2023~2026 2026
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
161 patients treated with standard-of-care therapies with early stage disease (both fresh frozen and formalin-fixed paraffin-embedded [FFPE] samples) or 121 patients with metastatic setting (primary tumor FFPE samples).
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In conclusion, a substantial proportion of MSS RASmt CCs exhibit high ISIC scores, meriting evaluation in prospective trials of immunotherapy-based combination regimens.

Dienstmann R, García-Galea E, O'Farrell A, Kinsella Z, Meylan M, Petitprez F

📝 환자 설명용 한 줄

To explore the immune microenvironment of RAS-mutated (RASmt) microsatellite stable (MSS) colon cancer (CC), we retrospectively performed whole exome sequencing, RNA sequencing, and robust digital pat

이 논문을 인용하기

↓ .bib ↓ .ris
APA Dienstmann R, García-Galea E, et al. (2026). Interrogating the immune landscape of microsatellite stable RAS-mutated colon cancer.. Molecular oncology. https://doi.org/10.1002/1878-0261.70225
MLA Dienstmann R, et al.. "Interrogating the immune landscape of microsatellite stable RAS-mutated colon cancer.." Molecular oncology, 2026.
PMID 41733106 ↗

Abstract

To explore the immune microenvironment of RAS-mutated (RASmt) microsatellite stable (MSS) colon cancer (CC), we retrospectively performed whole exome sequencing, RNA sequencing, and robust digital pathology analyses and studied immune markers in a cohort of 161 patients treated with standard-of-care therapies with early stage disease (both fresh frozen and formalin-fixed paraffin-embedded [FFPE] samples) or 121 patients with metastatic setting (primary tumor FFPE samples). Only a small proportion of cases exhibited a highly infiltrated immune microenvironment, with a strong association between Immunoscore (IS)-high (13% of the samples) and Tumor Lymphocytes Infiltrating Score (TuLIS)-high scores (25% of the samples). Immunoscore Immune-Checkpoint (ISIC)-high tumors (52% of the samples) shared a similar microenvironment composition to IS-high and TuLIS-like high tumors and displayed higher mutational burdens than ISIC-low tumors. In conclusion, a substantial proportion of MSS RASmt CCs exhibit high ISIC scores, meriting evaluation in prospective trials of immunotherapy-based combination regimens.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (1)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반